Abstract
Positive phase III trials are not truly practice changing if they do not accurately inform on the best options for patients
MeSH terms
-
Antineoplastic Agents* / therapeutic use
-
Humans
-
Male
-
Poly(ADP-ribose) Polymerase Inhibitors / adverse effects
-
Prostatic Neoplasms, Castration-Resistant* / drug therapy
-
Prostatic Neoplasms, Castration-Resistant* / pathology
Substances
-
Poly(ADP-ribose) Polymerase Inhibitors
-
Antineoplastic Agents